Literature DB >> 12216103

Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

Andrea Baur1, Axel Stäbler, Dorothea Nagel, Rolf Lamerz, Reiner Bartl, Erhard Hiller, Clemens Wendtner, Fridleif Bachner, Maximilian Reiser.   

Abstract

BACKGROUND: This study evaluated the prognostic value of a three-grade staging system of spinal involvement using magnetic resonance imaging (MRI) in patients with multiple myeloma and determined its usefulness as an independent parameter in the staging system of Durie and Salmon.
METHODS: Seventy-seven previously untreated patients with multiple myeloma underwent MRI of the thoracic and lumbar spine with unenhanced T1-weighted spin echo and short-tau inversion time inversion recovery sequences. The patients were evaluated according to their infiltration patterns and the extent of bone marrow involvement was staged using a three-grade scale: Stage I, no focal or diffuse infiltration; Stage II, 1-10 foci or mild diffuse infiltration; Stage III, more than 10 foci or strong diffuse infiltration.
RESULTS: The infiltration patterns had no significant effect on survival. Of 77 patients, 25 would have been understaged using the standard staging system of Durie and Salmon without the findings of MRI and 8 patients would have been understaged if the staging was based only on MRI. The combination of the staging system of Durie and Salmon and MRI was highly significant with respect to survival (P < 0.0001, log rank analysis). MRI staging I-III was independent of the staging system of Durie and Salmon (Cox regression model).
CONCLUSIONS: A three-grade staging of spinal MRI provides a significant prognostic tool for patients with multiple myeloma. The authors propose including it in the staging system of Durie and Salmon. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 12216103     DOI: 10.1002/cncr.10818

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  [Possibilities of whole-body MRI for investigating musculoskeletal diseases].

Authors:  S Lenk; S Fischer; I Kötter; C D Claussen; H P Schlemmer
Journal:  Radiologe       Date:  2004-09       Impact factor: 0.635

Review 2.  The uses and limitations of whole-body magnetic resonance imaging.

Authors:  Gerwin Schmidt; Dietmar Dinter; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Dtsch Arztebl Int       Date:  2010-06-04       Impact factor: 5.594

3.  Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study.

Authors:  Giuseppe Lucio Cascini; Carmela Falcone; Domenico Console; Antonino Restuccia; Marco Rossi; Antonello Parlati; Oscar Tamburrini
Journal:  Radiol Med       Date:  2013-06-26       Impact factor: 3.469

Review 4.  The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma.

Authors:  Jo Caers; Nadia Withofs; Jens Hillengass; Paolo Simoni; Elena Zamagni; Roland Hustinx; Yves Beguin
Journal:  Haematologica       Date:  2014-04       Impact factor: 9.941

Review 5.  Total-body MR-imaging in oncology.

Authors:  Juergen F Schaefer; Heinz-Peter W Schlemmer
Journal:  Eur Radiol       Date:  2006-04-19       Impact factor: 5.315

Review 6.  [Whole body MRI--diagnostic strategy of the future?].

Authors:  M Goyen; H-P Schlemmer
Journal:  Radiologe       Date:  2007-10       Impact factor: 0.635

7.  Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey.

Authors:  Nadir Ghanem; Christian Lohrmann; Monika Engelhardt; Gregor Pache; Markus Uhl; Ulrich Saueressig; Elmar Kotter; Mathias Langer
Journal:  Eur Radiol       Date:  2006-02-04       Impact factor: 5.315

Review 8.  The evolving role of MRI in oncohaematological disorders.

Authors:  O Tamburrini; M A Cova; D Console; P Martingano
Journal:  Radiol Med       Date:  2007-07-24       Impact factor: 3.469

Review 9.  Functional and molecular MRI of the bone marrow in multiple myeloma.

Authors:  Vassilis Koutoulidis; Nickolas Papanikolaou; Lia A Moulopoulos
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

10.  [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Authors:  S C Brandelik; J Krzykalla; T Hielscher; J Hillengass; J K Kloth; H U Kauczor; M A Weber
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.